#United States #San Diego #Neurocrine Biosciences #VYKAT XR #Soleno Therapeutics

Neurocrine Biosciences to Acquire Soleno Therapeutics

In a monumental move to enhance its presence in the endocrinology and rare disease sectors, Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has announced a definitive agreement to acquire Soleno Therapeutics, Inc. (Nasdaq: SLNO) for a cash transaction valued at $53.00 per share. This acquisition, totaling approximately $2.9 billion in equity, is expected to significantly bolster Neurocrine's portfolio, which already includes promising treatments such as INGREZZA® and CRENESSITY®.

The Significance of VYKAT™ XR

One of the primary assets gaining attention in this acquisition is VYKAT™ XR (diazoxide choline), the first FDA-approved treatment specifically designed to manage hyperphagia, a critical symptom associated with Prader-Willi syndrome (PWS). VYKAT XR has been celebrated for its transformative potential since its successful U.S. launch in the second quarter of 2025, amassing $190 million in revenue during its inaugural year.

Prader-Willi syndrome is a complex and rare genetic disorder caused by an anomaly on chromosome 15. It affects roughly 10,000 patients in the United States, manifesting challenges such as significant neurological, behavioral, and metabolic dysfunctions. The hallmark symptom, hyperphagia, leads to insatiable hunger, which can result in severe medical complications if not managed correctly. With VYKAT XR, Neurocrine aims to enhance the quality of life for PWS patients, addressing a critical unmet medical need that has previously hampered effective treatments.

Strategic Benefits for Neurocrine

The acquisition is a strategic move aligned with Neurocrine's mission to deliver life-altering therapies. Kyle W. Gano, Ph.D., the CEO of Neurocrine, emphasized that this merger would boost revenue growth while diversifying their therapeutic portfolio. Neurocrine will leverage its robust infrastructure and experience in the endocrinology field to expand the reach of VYKAT XR, ensuring it does not just benefit a niche population but becomes a foundational treatment for many.

Dr. Anish Bhatnagar, CEO of Soleno, echoed this sentiment by stating that collaborating with Neurocrine represents a vital step forward in amplifying the impact of VYKAT XR within the PWS community, capitalizing on Neurocrine’s proven commercial strategies.

Financial Outlook

Following the acquisition, the combined entity will feature three innovative first-in-class drugs: VYKAT XR for PWS, INGREZZA® for tardive dyskinesia, and CRENESSITY® for congenital adrenal hyperplasia. This diversification is projected to lead to sustained revenue growth through the upcoming decade, with synergy opportunities stemming from operational efficiencies and cost management.

The financial strategy surrounding the transaction involves using cash reserves, with plans to possibly integrate some modest debt—ensuring a flexible and robust balance sheet moving forward. The closing of this deal is anticipated within 90 days, pending standard regulatory approval and market conditions.

Next Steps

Neurocrine plans to provide further insights about the acquisition during a scheduled conference call today at 8:00 AM ET. This call will be pivotal in clarifying the immediate and long-term implications of the merger, alongside discussing the anticipated impact on stakeholders and the wider PWS community.

Conclusion

With this acquisition, Neurocrine Biosciences is not just broadening its portfolio; it is reinforcing its commitment to developing treatment options for rare diseases that can significantly change patients' lives. The future of therapies like VYKAT XR may well reshape the landscape of treatments available for Prader-Willi syndrome and set a new standard for how such complex conditions are managed.